Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Putative adhesion molecule that mediates sialic-acid dependent binding to cells. Additionally we are shipping SIGLEC9 Proteins (7) and SIGLEC9 Kits (2) and many more products for this protein.
Showing 10 out of 149 products:
Human Polyclonal SIGLEC9 Primary Antibody for EIA, IHC (p) - ABIN357151
Zhang, Nicoll, Jones, Crocker: Siglec-9, a novel sialic acid binding member of the immunoglobulin superfamily expressed broadly on human blood leukocytes. in The Journal of biological chemistry 2000
Show all 5 references for ABIN357151
Human Monoclonal SIGLEC9 Primary Antibody for FACS, IF - ABIN2658391
Ikehara, Ikehara, Paulson: Negative regulation of T cell receptor signaling by Siglec-7 (p70/AIRM) and Siglec-9. in The Journal of biological chemistry 2004
Show all 3 references for ABIN2658391
Human Monoclonal SIGLEC9 Primary Antibody for FACS - ABIN2662845
von Gunten, Yousefi, Seitz, Jakob, Schaffner, Seger, Takala, Villiger, Simon: Siglec-9 transduces apoptotic and nonapoptotic death signals into neutrophils depending on the proinflammatory cytokine environment. in Blood 2005
Show all 3 references for ABIN2662845
Binding studies on recombinant human Siglec-9 show recognition of both Neu5Ac and Neu5Gc; in striking contrast, chimpanzee and gorilla Siglec-9 strongly prefer binding Neu5Gc.
Constitutively expressed Siglec-9 inhibits LPS (show IRF6 Antibodies)-induced CCR7 (show CCR7 Antibodies), but enhances IL-4 (show IL4 Antibodies)-induced CD200R (show CD200R1 Antibodies) expression in human macrophages.
Ligands for Siglec-8 (show SIGLEC8 Antibodies) and Siglec-9 may regulate the function of eosinophils, mast cells, neutrophils, and other cells in sinus mucosa.
Inflammation results in up-regulation of immuneinhibitory Siglec-8 (show SIGLEC8 Antibodies) and Siglec-9 sialoglycan ligands on human airways.
a polymorphism that reduced Siglec-9 binding to carcinomas was associated with improved early survival in non-small-cell lung ca (show CD33 Antibodies)ncer patients
Dasatinib enhances migration of monocyte-derived dendritic cells by reducing phosphorylation of inhibitory immune receptors Siglec-9 and Siglec-3 (show CD33 Antibodies).
Expression of Siglec-7 (show SIGLEC7 Antibodies) and -9 ligands was associated with susceptibility of NK cell-sensitive tumor cells and, unexpectedly, of presumably NK cell-resistant tumor cells to NK cell-mediated cytotoxicity.
Protein degradation of focal adhesion kinase and related molecules was induced by Siglec-9 binding to its counterreceptors via sialylglycoconjugates, leading to the modulation of adhesion kinetics of cancer cells.
Siglec-9 expressed on immune cells may play a role as a potential counterreceptor for MUC1 (show MUC1 Antibodies) and that this signaling may be another MUC1 (show MUC1 Antibodies)-mediated pathway and function in parallel with a growth factor-dependent pathway.
The Siglec-9 peptide binding to the enzymatic groove of VAP-1 (show AOC3 Antibodies) can be used for imaging conditions, such as inflammation and cancer.
Siglec-9 A391C was the only polymorphism related to TCR-mediated signaling in human Siglec-9, resulting in less inhibition compared to the wild type.
indicate that Siglec-9 affects several different signaling pathways in IL-4 (show IL4 Antibodies)-stimulated macrophages, which resulted in enhanced induction of Arg1 (show ARG1 Antibodies) in Siglec-9-expressing RAW264 cells
Competitive ELISA assays confirmed the involvement of sulfated (show SULF1 Antibodies) epitopes in the affinity between Siglec-E and cruzipain, probably modified by natural protein environment
Data indicate a role for neuraminidase 1 (Neu1 (show NEU1 Antibodies)) in regulating Siglec E protein-toll-like receptor 4 (TLR4 (show TLR4 Antibodies)) interaction and endotoxemia.
Siglec-E-deficient macrophages showed a propensity toward a tumor-promoting M2 polarization, indicating a secondary role of CD33 (show CD33 Antibodies)-related Siglecs in limiting cancer-promoting inflammation and tumor growth.
siglec-E functions as an inhibitory receptor of neutrophils via positive regulation of NADPH oxidase (show NOX1 Antibodies) activation and ROS (show ROS1 Antibodies) production
These results suggest that sSiglec-9 has an antitumor benefit against MUC1 (show MUC1 Antibodies)-expressing tumor in the transgenic mice.
Siglec-E is induced in a MyD88 (show MYD88 Antibodies)-dependent manner. Once up-regulated, it can control TLR-dependent NF-kappaB (show NFKB1 Antibodies) antiviral responses by directly inhibiting TLR-induced antiviral cytokine production.
Putative adhesion molecule that mediates sialic-acid dependent binding to cells. The sialic acid recognition site may be masked by cis interactions with sialic acids on the same cell surface. In the immune response, may act as an inhibitory receptor upon ligand induced tyrosine phosphorylation by recruiting cytoplasmic phosphatase(s) via their SH2 domain(s) that block signal transduction through dephosphorylation of signaling molecules.
sialic acid-binding immunoglobulin-like lectin 9
, sialic acid binding Ig-like lectin 9
, protein FOAP-9
, sialic acid-binding Ig-like lectin 9
, SIGLEC-like 1
, myeloid inhibitory siglec
, sialic acid binding Ig-like lectin 5
, sialic acid-binding Ig-like lectin 12
, sialic acid-binding Ig-like lectin 5
, sialic acid-binding Ig-like lectin E
, sialic acid-binding Ig-like lectin-like 1
, sialic acid-binding immunoglobulin-like lectin E